OMER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Omeros Corp (OMER) is not a strong buy for a beginner investor with a long-term strategy at this time. While there are positive technical indicators and hedge fund buying activity, the company's financial performance is significantly weak, with a sharp decline in net income and EPS. Additionally, there are no strong proprietary trading signals or recent influential trades to justify immediate action.
The technical indicators show a bullish trend with MACD above 0, positively contracting, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). RSI is neutral at 77.562, and the stock is trading above its pivot level of 12.615, with resistance at 13.643 and 14.278.
Hedge funds are significantly increasing their buying activity, up 185085.19% in the last quarter.
The company announced a permanent J-code for its treatment Yartemlea, simplifying claims processing and enhancing patient access.
European approval for Yartemlea is anticipated by mid-2026.
Financial performance is weak, with net income dropping -375.69% YoY and EPS down -325.93% YoY in Q4
No recent insider or congress trading activity to indicate confidence in the stock.
The stock has an 80% chance to decline -0.5% in the next day.
In Q4 2025, revenue remained stagnant at 0 (0.00% YoY), while net income dropped to 86.45M (-375.69% YoY) and EPS fell to 1.22 (-325.93% YoY). Gross margin also showed no improvement.
No recent analyst rating or price target changes available for OMER.
